LANTERN PHARMA INC (LTRN)

LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024

LTRN stock results show that Lantern Pharma missed analyst estimates for earnings per share the first quarter of 2024.

LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lantern Pharma (NASDAQ:LTRN) just reported results for the first quarter of 202...

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire

Keep an eye on machine learning stocks. With big demand, we could be looking at a half-trillion-dollar market by 2030.

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth

EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(NYSE:MDT),(NASDAQ:NVDA),(NASDAQ:LTRN),(OTCQX:HWAIF),(TSX:AIDX) EQNX::TICKER_END

Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth

/PRNewswire/ -- With the increase in life expectancy, people need more medical help and care. AI-enabled technologies can help people to live healthier and...

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(OTCQX:HWAIF),(OTCQB:VRSSF),(NYSE:PATH),(NASDAQ:LTRN) EQNX::TICKER_END

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023

LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lantern Pharma (NASDAQ:LTRN) just reported results for the fourth quarter of 20...

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom

Discover how these AI powerhouses are leveraging AI in the IT consulting, application software, and biotech industries.

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer